Neo Ivy Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Neo Ivy Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5M	Buy	+10,195	New	+$2.21M	0.57%	60
2025 Q2	–	Sell	-350	Closed	-$40.8K	–	359
2025 Q1	$40.8K	Buy	+350	New	+$39.9K	0.01%	248
2023 Q4	–	Sell	-2,912	Closed	-$204K	–	296
2023 Q3	$204K	Buy	+2,912	New	+$218K	0.09%	226
2022 Q4	–	Sell	-225	Closed	-$10K	–	336
2022 Q3	$10K	Buy	+225	New	+$11.2K	0.03%	320
2020 Q4	–	Sell	-950	Closed	-$67K	–	417
2020 Q3	$67K	Buy	+950	New	+$74K	0.07%	334

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neo Ivy Capital Management's AXSM Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 10,195 shares worth $2.5M. The stake represents 0.57% of the portfolio and ranks #60 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in AXSM as recently as Q1 2025.

Neo Ivy Capital Management first reported a position in AXSM in Q3 2020 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Neo Ivy Capital Management held 10,195 shares of Axsome Therapeutics worth $2.5M as of Q2 2026.
Axsome Therapeutics was a new Neo Ivy Capital Management position in Q2 2026.
Axsome Therapeutics made up 0.57% of Neo Ivy Capital Management's portfolio in Q2 2026, its #60 holding.
Neo Ivy Capital Management first reported a position in Axsome Therapeutics in Q3 2020 and has held it in 5 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.